Study of Serine Supplementation to Protect Vision in MacTel

Part of paid clinical trials in La Jolla, California.

Sponsor
The Lowy Medical Research Institute Limited
Study ID
NCT07342439
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Macular Telangiectasia Type 2 (MacTel)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • L-serine — DRUG
    L-serine powder administered twice daily
  • Placebo — OTHER
    Placebo powder administered twice daily

Study Details

The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2. The main questions it aims to answer are: * Does serine slow the progression of MacTel? * Is long-term serine supplementation safe in people with MacTel? Researchers will compare serine to a placebo (a look-alike substance that contains no drug) to see if serine works to slow the progression of MacTel. Participants will: * Take serine or a placebo twice a day for 24 months * Visit the clinic once every 6 months for eye exam, eye imaging and blood tests * Keep a diary of their symptoms, missed doses, and changes in medications

Key Dates

Start date
Sep 30, 2026
Status verified
Jan 2026
Primary completion
Nov 30, 2029
Completion
Feb 28, 2030

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: L-serine
    Participant receives oral L-serine
  • Placebo Comparator: Placebo
    Participant receives placebo

Primary Outcome Measure

EZ loss [ Time Frame: Baseline through Month 24 ]

Locations (4)

FacilityCityStateZIPSite coordinators
Hamilton Glaucoma Center- UCSDLa JollaCalifornia92093
Veronica Study Coordinator
[email protected]
858-822-1896
Chrisopher Toomey, MD, PhD (PRINCIPAL_INVESTIGATOR)
University of Michigan, Kellogg Eye CenterAnn ArborMichigan48105
Maddie Study Coordinator
[email protected]
734-936-0138
Courtney Study Coordinator
[email protected]
734-936-9798
Grant Comer, MD (PRINCIPAL_INVESTIGATOR)
Retina Associates Of Cleveland, Inc.ClevelandOhio44122
Diane Study Coordinator
[email protected]
216-831-5704
LAWRENCE SINGERMAN, MD (PRINCIPAL_INVESTIGATOR)
University of Utah Health Care, Moran Eye CenterSalt Lake CityUtah84132
Barbara Study Coordinator
[email protected]
801-581-6459
Kimberley Study Coordinator
[email protected]
858-584-6265
Paul Bernstein, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in La Jolla, CA

By research site
Hamilton Glaucoma Center- UCSD· La Jolla, CAUniversity of Michigan, Kellogg Eye Center· Ann Arbor, MIRetina Associates Of Cleveland, Inc.· Cleveland, OHUniversity of Utah Health Care, Moran Eye Center· Salt Lake City, UT

Related Studies